SOLICITATION NOTICE
Q -- Services regarding Mutation Testing of RBI in Individuals from a Retinoblastoma Cohort
- Notice Date
- 8/20/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100196-AV
- Archive Date
- 9/22/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis with Retinoblastoma Solutions c/o/ Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8 CANADA for services regarding Mutation Testing of RBI in Individuals from a Retinoblastoma Cohort. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be for twelve months from date of award. Retinoblastoma (RB) is a rare childhood cancer that has contributed enormously to a basic understanding of carcinogenesis. Four decades ago, Knudson developed his hypothesis of tumor suppressor genes based on the inheritance of retinoblastoma within families. With the discovery of the RB1 gene it became possible to evaluate mutation-specific outcomes, but these studies have been limited because of the difficulty of mutation testing in this large 27-exon gene and the rarity of the cancer. The NCI has a rare opportunity to evaluate the genotype-phenotype associations among a cohort of retinoblastoma survivors, many of whom have heritable retinoblastoma and some of whom have developed second tumors, either malignant or benign. The cohort has been followed for over twenty years, and has published data on cancer incidence, mortality, and patterns of second and other multiple cancers. Since RB1 was identified as the gene for retinoblastoma, two other tumor suppressor genes of major interest, P53 and CDKN2A have been identified as major susceptibility genes for Li-Fraumeni syndrome and familial melanoma. Both of these genes are in pathways closely related to RB1, and the tumors associated with mutations in these genes (bone and soft tissue sarcomas and melanoma) are the most frequent second cancers after heritable retinoblastoma in this cohort. It is plausible that location-specific mutations in RB1 could predict risk of sarcomas or melanomas following heritable RB. The contractor shall provide high quality mutation testing for highly characterized individuals with retinoblastoma and second tumors. These samples are unique; many of the individuals are now deceased and it is imperative to have the highest quality testing possible, since these samples are irreplaceable. The contractor must have demonstrated a very high success rate in completing RB1 mutation testing in previous samples. The contractor shall conduct mutation testing for RB1 in DNA samples provided by the NCI from the RB cohort followed by the NCI for over 20 years. Mutation testing for the RB1 gene is highly technologically challenging. Standardized handling of the DNA and reagents is crucial for accurate determination of the mutations. There is no other known facility with comparable experience in the world and no other facility that focuses exclusively on RB1 mutation detection. Over the years, Retinoblastoma Solutions has perfected the technology and is currently the world's preeminent laboratory for this diagnostic test; they receive samples from around the world and evaluate over 100 new families per year. They also have the highest rates of mutation detection (approximately 95% for bilateral cases and 93% for unilateral familial) and are uniquely capable of handling this many samples. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on September 7, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at (301) 435-3817. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100196-AV on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100196-AV/listing.html)
- Record
- SN02249206-W 20100822/100820235550-ae32be13777b652ca5e18a5e63f764bf (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |